| 产品名称 | AlphaThera | AT7003 | oYo-Link® VcMMAF |
|---|---|
| 目录号 | AT7003 |
| 别名 | AT7003 |
| 外观 | 见COA |
| 分子量 | N/A |
| CAS | N/A |
| 溶解度 | |
| 存储条件 | 见COA |
| 保存时间 | 见COA |
| 备注1 | |
| 备注2 |
| 目录号 | 规格 | 价格 | 库存状态 | |
| AT7003 | 100 μg; Bulk | 咨询 | 咨询 |
AlphaThera | AT7003 | oYo-Link® VcMMAF
品名:oYo-Link® VcMMAF
货号:AT7003
规格:100 μg; Bulk
品牌:AlphaThera
产品描述
Site-specifically label your antibody with oYo-Link® VcMMAF for cell killing assays to prototype your ADC candidates.
oYo-Link® VcMMAF is an Antibody-Drug Conjugation reagent allowing for site-specific labeling of VcMMAF (Monomethyl Auristatin F) labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAF is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAF drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAF drugs to be attached per antibody, providing precise antibody-drug conjugate ratios.
Applications:Antibody conjugation reagent for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays.